CA
NZ
UK
AU
IND
US
…
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Syndax Pharmaceuticals is a clinical-stage biotech developing oncology treatments, focused on epigenetic modulators and combination regimens. Long-term growth may be driven by clinical progress of its HDAC inhibitor programs, regulatory milestones, and partnerships that could support development and commercialization.
Key risks include high clinical and regulatory uncertainty, limited revenues and cash runway requiring additional financing, and competitive pressures in oncology that could hinder adoption.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M |
| Net income | -143.75M | 24.93M | -73.07M | -55.95M | -73.96M |
| Selling general administrative | 33.26M | 25.24M | 22.50M | 16.06M | 17.29M |
| Gross profit | - | 139.71M | 1.52M | 1.52M | 1.52M |
| Reconciled depreciation | 0.03M | 0.04M | 0.09M | 0.09M | 0.08M |
| Ebit | -151.79M | 26.18M | -71.51M | -57.63M | -75.95M |
| Ebitda | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M |
| Depreciation and amortization | 0.03M | 0.04M | 0.09M | 0.09M | 0.08M |
| Non operating income net other | - | 0.60M | 0.62M | -0.08M | -0.03M |
| Operating income | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M |
| Other operating expenses | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M |
| Interest expense | 3.14M | 1.90M | 2.36M | 1.57M | 1.94M |
| Interest income | 5.87M | 0.40M | 0.84M | 1.57M | 1.94M |
| Net interest income | 2.73M | -1.50M | -1.52M | 1.57M | 1.94M |
| Income tax expense | -5.59M | -0.04M | -0.09M | -0.09M | 1.92M |
| Total revenue | 0.00M | 139.71M | 1.52M | 1.52M | 1.52M |
| Total operating expenses | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M |
| Net income from continuing ops | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M |
| Net income applicable to common shares | -149.34M | 24.93M | -77.06M | -56.05M | -73.96M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 612.88M | 497.24M | 449.66M | 300.61M | 63.52M |
| Other current assets | 0.06M | 0.19M | 0.38M | 0.34M | 0.76M |
| Total liab | 58.68M | 29.79M | 41.29M | 48.42M | 31.93M |
| Total stockholder equity | 554.20M | 467.45M | 408.37M | 252.19M | 31.60M |
| Other current liab | 0.89M | 24.28M | 1.89M | 11.25M | 10.20M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -902.40M | -693.04M | -543.70M | -568.63M | -495.47M |
| Other liab | - | - | - | 11.62M | 13.14M |
| Other assets | - | 0.92M | 449.66M | 1.56M | 0.20M |
| Cash | 295.39M | 74.36M | 221.97M | 115.24M | 24.61M |
| Total current liabilities | 58.10M | 29.07M | 20.68M | 18.87M | 18.37M |
| Current deferred revenue | 38.97M | - | 12.76M | 1.52M | 1.52M |
| Net debt | -293.76M | -73.19M | -201.00M | -94.71M | -23.71M |
| Short term debt | 1.05M | 0.44M | 0.36M | 2.60M | 0.48M |
| Short long term debt | - | - | - | 2.29M | - |
| Short long term debt total | 1.64M | 1.16M | 20.97M | 20.54M | 0.90M |
| Other stockholder equity | 1456.37M | 1161.29M | 952.02M | 820.82M | 527.07M |
| Property plant equipment | - | 1.06M | 0.28M | 0.19M | 1.00M |
| Total current assets | 580.88M | 481.27M | 448.40M | 298.86M | 62.33M |
| Long term investments | 29.83M | 5.47M | - | - | - |
| Net tangible assets | - | 467.45M | 408.37M | 252.19M | 31.60M |
| Short term investments | 282.19M | 410.04M | 217.97M | 177.82M | 35.17M |
| Net receivables | 1.23M | 4.06M | 0.43M | 0.17M | 0.12M |
| Long term debt | - | - | 19.89M | 17.83M | - |
| Inventory | 2.00M | -4.25M | 7.65M | 5.28M | 1.68M |
| Accounts payable | 17.19M | 4.35M | 5.67M | 3.51M | 6.18M |
| Accumulated other comprehensive income | 0.22M | -0.81M | 0.04M | -0.00M | -0.31M |
| Common stock total equity | - | - | 0.01M | 0.01M | 0.00M |
| Retained earnings total equity | - | - | -543.70M | -568.63M | -495.47M |
| Non currrent assets other | 0.68M | 9.44M | 0.98M | 1.27M | 0.20M |
| Non current assets total | 32.00M | 15.96M | 1.26M | 1.75M | 1.19M |
| Capital lease obligations | 1.64M | 1.16M | 1.07M | 0.42M | 0.90M |
| Long term debt total | - | - | 19.89M | 17.83M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -186.19M | -40.74M | -142.53M | 12.78M | 51.59M |
| Change to liabilities | -1.32M | 4.93M | -2.10M | 1.33M | 0.18M |
| Total cashflows from investing activities | -186.19M | -40.87M | -142.53M | 12.78M | 51.40M |
| Net borrowings | -21.00M | -21.00M | 19.73M | 19.73M | 19.73M |
| Total cash from financing activities | 172.25M | 118.46M | 304.42M | 28.57M | 15.73M |
| Change to operating activities | 2.98M | 1.38M | -3.75M | -3.46M | 2.01M |
| Net income | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M |
| Change in cash | -147.61M | 106.72M | 90.63M | -9.26M | -1.40M |
| Begin period cash flow | 222.08M | 115.36M | 24.72M | 33.98M | 35.39M |
| End period cash flow | 74.47M | 222.08M | 115.36M | 24.72M | 33.98M |
| Total cash from operating activities | -133.68M | 29.13M | -71.26M | -50.61M | -68.53M |
| Issuance of capital stock | 181.79M | 86.34M | 277.71M | 28.21M | 15.50M |
| Depreciation | 0.03M | 0.04M | 0.09M | 0.09M | 0.08M |
| Other cashflows from investing activities | - | - | - | 12.78M | 51.59M |
| Sale purchase of stock | - | 24.85M | 284.69M | 28.57M | 15.72M |
| Other cashflows from financing activities | 11.46M | 7.28M | 26.71M | 0.36M | 0.23M |
| Change to netincome | 13.97M | 12.93M | 9.45M | 6.00M | 6.21M |
| Capital expenditures | 0.00M | 0.13M | 0.13M | 0.13M | 0.19M |
| Cash flows other operating | - | -14.30M | -5.32M | -1.21M | -0.48M |
| Cash and cash equivalents changes | - | 106.72M | 90.63M | -9.26M | -1.40M |
| Change in working capital | 1.66M | -9.60M | -7.93M | -0.24M | -0.30M |
| Stock based compensation | 16.02M | 13.32M | 9.06M | 6.00M | 6.20M |
| Other non cash items | -2.04M | 0.19M | 0.82M | 0.36M | 0.01M |
| Free cash flow | -133.68M | 29.00M | -71.26M | -50.61M | -68.72M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals Inc |
-0.50 3.53% |
13.65 | - | - | 12.67 | 3.33 | 9.00 | -6.08 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael A. Metzger M.B.A. | CEO & Director | 1971 |
| Dr. Briggs W. Morrison M.D. | Pres, Head of R&D and Director | 1960 |
| Dr. Anjali Ganguli Ph.D. | Chief Bus. Officer | 1976 |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | 1969 |
| Dr. Richard A. Heyman Ph.D. | Co-Founder | 1957 |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | NA |
| Dr. Michael Downes Ph.D. | Co-Founder | NA |
| Mr. Keith Alan Goldan CPA | Chief Financial Officer | 1971 |
| Mr. Alexander Nolte | VP & Chief Accounting Officer | 1973 |
| Sharon Klahre | VP of Investor Relations & Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...